Helen Won

16.5k total citations · 3 hit papers
61 papers, 4.1k citations indexed

About

Helen Won is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Helen Won has authored 61 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 23 papers in Oncology and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Helen Won's work include Cancer Genomics and Diagnostics (14 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Research Studies (9 papers). Helen Won is often cited by papers focused on Cancer Genomics and Diagnostics (14 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Research Studies (9 papers). Helen Won collaborates with scholars based in United States, United Kingdom and Japan. Helen Won's co-authors include Michael F. Berger, Marc Ladanyi, Sarat Chandarlapaty, José Baselga, Zhiqiang Li, David Chen, Gabriel N. Hortobágyi, Weiyi Toy, Geoffrey L. Greene and Kinisha Gala and has published in prestigious journals such as Nature, Nature Communications and Nature Genetics.

In The Last Decade

Helen Won

60 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

2013 855 citations Helen Won, Michael F. Berger et al. profile →
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets

2016 325 citations Natasha Rekhtman, M. Catherine Pietanza et al. Clinical Cancer Research profile →
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden

2019 289 citations Ryma Benayed, Michael Offin et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Helen Won

Since Specialization

Citations

This map shows the geographic impact of Helen Won's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Won with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Won more than expected).

Fields of papers citing papers by Helen Won

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Won. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Won. The network helps show where Helen Won may publish in the future.

Co-authorship network of co-authors of Helen Won

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Won. A scholar is included among the top collaborators of Helen Won based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Won. Helen Won is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC). 2024 ·Journal of Clinical Oncology ·Sherene Loi, Stephen Johnston, Carlos L. Arteaga, Stephanie L. Graff, Sarat Chandarlapaty, Matthew P. Goetz, Christine Desmedt, Hironobu Sasano, Deli Liu, Vanessa Rodrik-Outmezguine, Anthony Sireci, (unknown), Helen Won, Lacey M. Litchfield, Nicholas C. Turner	12
2	3MO Analysis of germline BRCA1/2 mutations and uncommon somatic alterations from patients with HR+, HER2-, node-positive, high-risk early breast cancer enrolled in monarchE 2024 ·ESMO Open ·Christine Desmedt, Nicholas C. Turner, Carlos L. Arteaga, Hironobu Sasano, Stephanie L. Graff, Sherene Loi, (unknown), Dan Liu, Vanessa Rodrik-Outmezguine, Anthony Sireci, (unknown), Helen Won, (unknown), Montserrat Muñoz-Mateu, (unknown)	4
3	Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers 2022 ·Clinical Cancer Research ·Felipe Batalini, D. Gulhan, (unknown), (unknown), Madeline Polak, Niya Xiong, Nabihah Tayob, Nadine Tung, Eric P. Winer, Erica L. Mayer, Stian Knappskog, Per Eystein Lønning, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos, David B. Solit, Helen Won, Hans Petter Eikesdal, Peter J. Park, Gerburg M. Wulf	22
4	High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden breakdown → 2019 ·Clinical Cancer Research ·Ryma Benayed, Michael Offin, Kerry Mullaney, Purvil Sukhadia, Kelly Rios, Patrice Desmeules, Ryan Ptashkin, Helen Won, Jason C. Chang, Darragh Halpenny, Alison M. Schram, Charles M. Rudin, David M. Hyman, Maria E. Arcila, Michael F. Berger, Ahmet Zehir, Mark G. Kris, Alexander Drilon, Marc Ladanyi	289
5	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer 2019 ·npj Breast Cancer ·Mellissa J. Nixon, Luigi Formisano, Ingrid A. Mayer, Mónica V. Estrada, Paula I. González-Ericsson, Steven J. Isakoff, Andres Forero‐Torres, Helen Won, Melinda E. Sanders, David B. Solit, Michael F. Berger, Lewis C. Cantley, Eric P. Winer, Carlos L. Arteaga, Justin M. Balko	28
6	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer 2018 ·Cancer Cell ·Craig M. Bielski, Mark T.A. Donoghue, Mayur Gadiya, Aphrothiti J. Hanrahan, Helen Won, Matthew T. Chang, Philip Jonsson, Alexander Penson, Alexander N. Gorelick, Christopher Harris, Alison M. Schram, Aijazuddin Syed, Ahmet Zehir, Paul B. Chapman, David M. Hyman, David B. Solit, Kevin Shannon, Sarat Chandarlapaty, Michael F. Berger, Barry S. Taylor	59
7	Genomic analyses reveal potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy 2017 ·Annals of Oncology ·Nina Radosevic‐Robin, Emiliano Cocco, Helen Won, M Berger, Maud Privat, Catherine Abrial, (unknown), (unknown)	1
8	Clinical and molecular characterization of patients with cancer of unknown primary in the modern era 2017 ·Annals of Oncology ·Anna M. Varghese, Arshi Arora, Marinela Capanu, Niedzica Camacho, Helen Won, Ahmet Zehir, Jianjiong Gao, Debyani Chakravarty, Nikolaus Schultz, David S. Klimstra, Marc Ladanyi, David M. Hyman, David B. Solit, Michael F. Berger, Leonard B. Saltz	73
9	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets breakdown → 2016 ·Clinical Cancer Research ·Natasha Rekhtman, M. Catherine Pietanza, Matthew D. Hellmann, Jarushka Naidoo, Arshi Arora, Helen Won, Darragh Halpenny, Hangjun Wang, Shaozhou K. Tian, Anya M. Litvak, Paul K. Paik, Alexander Drilon, Nicholas D. Socci, John T. Poirier, Ronglai Shen, Michael F. Berger, André L. Moreira, William D. Travis, Charles M. Rudin, Marc Ladanyi	325
10	A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer 2016 ·Clinical Cancer Research ·Ingrid A. Mayer, Vandana G. Abramson, Luigi Formisano, Justin M. Balko, Mónica V. Estrada, Melinda E. Sanders, Dejan Juric, David B. Solit, Michael F. Berger, Helen Won, Yisheng Li, Lewis C. Cantley, Eric P. Winer, Carlos L. Arteaga	241
11	Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology 2016 ·Modern Pathology ·Paul Weisman, Charlotte K.Y. Ng, Edi Brogi, (unknown), Helen Won, Salvatore Piscuoglio, Maria Rosaria De Filippo, (unknown), Muzaffar Akram, Larry Norton, Britta Weigelt, Michael F. Berger, Jorge S. Reis‐Filho, Hannah Y. Wen	85
12	Investigation of Somatic <b><i>GNAQ, GNA11, BAP1</i></b> and <b><i>SF3B1</i></b> Mutations in Ophthalmic Melanocytomas 2016 ·Ocular Oncology and Pathology ·Jasmine H. Francis, Thomas Wiesner, Tatyana Milman, Helen Won, Amy Lin, Vivian Lee, Daniel M. Albert, Robert Folberg, Michael F. Berger, Devron H. Char, Brian P. Marr, David H. Abramson	9
13	Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases 2015 ·Cancer Discovery ·Paul K. Paik, Ronglai Shen, Helen Won, Natasha Rekhtman, Lu Wang, Camelia S. Sima, Arshi Arora, Venkatraman Seshan, Marc Ladanyi, Michael F. Berger, Mark G. Kris	111
14	Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2) 2015 ·Modern Pathology ·Jaclyn F. Hechtman, Weiguo Liu, Justyna Sadowska, (unknown), Laetitia Borsu, Maria E. Arcila, Helen Won, Ronak Shah, Michael F. Berger, Efsevia Vakiani, Jinru Shia, David S. Klimstra	49
15	Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence 2014 ·Cancer Research ·Moriah H. Nissan, Christine A. Pratilas, Alexis M. Jones, Ricardo J. Ramirez, Helen Won, Cailian Liu, Shakuntala Tiwari, Li Ren Kong, Aphrothiti J. Hanrahan, Zhan Yao, Taha Merghoub, Antoni Ribas, Paul B. Chapman, Rona Yaeger, Barry S. Taylor, Nikolaus Schultz, Michael F. Berger, Neal Rosen, David B. Solit	219
16	Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes 2014 ·Journal of Thoracic Oncology ·Anna M. Varghese, Maureen F. Zakowski, Helena A. Yu, Helen Won, Gregory J. Riely, Lee M. Krug, Mark G. Kris, Natasha Rekhtman, Marc Ladanyi, Lu Wang, Michael F. Berger, M. Catherine Pietanza	102
17	Massively Parallel Sequencing Identifies Recurrent Mutations in TP53 in Thymic Carcinoma Associated with Poor Prognosis 2014 ·Journal of Thoracic Oncology ·André L. Moreira, Helen Won, Robert McMillan, James Huang, Gregory J. Riely, Marc Ladanyi, Michael F. Berger	50
18	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle 2014 ·Annals of Oncology ·Leticia De Mattos‐Arruda, Britta Weigelt, Javier Cortés, Helen Won, Charlotte K.Y. Ng, Paolo Nucíforo, François‐Clément Bidard, Claudia Aura, Cristina Saura, Vicente Peg, Salvatore Piscuoglio, Mafalda Oliveira, Yvonne H. C. M. Smolders, Pragi Patel, Larry Norton, Josep Tabernero, Michael F. Berger, Joan Seoane, Jorge S. Reis‐Filho	284
19	Is There Evidence of the New Variant Chlamydia trachomatis in the United States? 2013 ·Sexually Transmitted Diseases ·Helen Won, Padmini Ramachandran, Richard Steece, Barbara Van Der Pol, Jeanne Moncada, Julius Schachter, Charlotte A. Gaydos	6
20	Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing 2013 ·Journal of Visualized Experiments ·Helen Won, Sasinya N. Scott, A. Rose Brannon, Ronak Shah, Michael F. Berger	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact